$-0.40 EPS Expected for Kindred Biosciences, Inc. (KIN)

October 13, 2018 - By Michael Collier

Kindred Biosciences, Inc. (NASDAQ:KIN) LogoInvestors sentiment increased to 2 in Q2 2018. Its up 1.22, from 0.78 in 2018Q1. It increased, as 3 investors sold Kindred Biosciences, Inc. shares while 16 reduced holdings. 15 funds opened positions while 23 raised stakes. 19.86 million shares or 17.97% more from 16.83 million shares in 2018Q1 were reported.
24,391 are owned by Rhumbline Advisers. Tiaa Cref Mgmt Llc reported 53,119 shares. Barclays Public Limited Co has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 3,398 shares. Jpmorgan Chase & Communication reported 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). General American Investors holds 0.58% or 594,878 shares. Moreover, California State Teachers Retirement System has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). Sit Investment Associates reported 70,600 shares. Renaissance Tech Ltd Co accumulated 695,200 shares. Amer Gp has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). The New York-based Blackrock has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Legal & General Public Limited Com owns 3,739 shares for 0% of their portfolio. Eam Ltd Liability Company invested in 63,883 shares or 0.11% of the stock. Citadel Advsr Ltd Com owns 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 20,497 shares. Morgan Stanley reported 2.16 million shares. Citigroup reported 539 shares or 0% of all its holdings.

Since May 1, 2018, it had 1 insider purchase, and 7 insider sales for $6.24 million activity. On Wednesday, June 20 the insider Park West Asset Management LLC bought $8.03M.

Analysts expect Kindred Biosciences, Inc. (NASDAQ:KIN) to report $-0.40 EPS on November, 6.They anticipate $0.11 EPS change or 37.93 % from last quarter’s $-0.29 EPS. After having $-0.39 EPS previously, Kindred Biosciences, Inc.’s analysts see 2.56 % EPS growth. The stock increased 2.94% or $0.34 during the last trading session, reaching $11.9. About 383,832 shares traded or 88.86% up from the average. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 85.33% since October 14, 2017 and is uptrending. It has outperformed by 69.71% the S&P500.

Kindred Biosciences, Inc. (NASDAQ:KIN) Ratings Coverage

Among 5 analysts covering Kindred Biosciences (NASDAQ:KIN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Kindred Biosciences had 6 analyst reports since May 9, 2018 according to SRatingsIntel. As per Tuesday, August 7, the company rating was downgraded by Ladenburg Thalmann. As per Tuesday, June 26, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by FBR Capital on Tuesday, August 7. The firm earned “Buy” rating on Wednesday, May 9 by H.C. Wainwright.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $402.22 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Another recent and important Kindred Biosciences, Inc. (NASDAQ:KIN) news was published by Prnewswire.com which published an article titled: “Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare …” on September 17, 2018.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.